Ataxin-1 Monoclonal Antibody
Prices are excluding VAT and shipping costs
Product information
| Price | €240, €410 |
|---|---|
| Size | 50 µl/µg | 100 µl/µg |
| Short name | Ataxin-1 |
| Host | Mouse |
| Isotype | IgG |
| Target protein | ATXN1 |
| Recommended applications | ELISA, FCM, ICC, IF, IHC-p, WB |
| Reactivity | Human |
| Immunogen | Purified recombinant fragment of human Ataxin-1 expressed in E. Coli. |
| Purification | Affinity purification |
| Formulation | Ascitic fluid containing 0.03% sodium azide;0.5% BSA; 50%glycerol. |
| Storage | -20°C for 1 year |
| Product code | MB-AM10458 |
Additional information
Prev
Next
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted
ATXN1, ATX1, SCA1, Ataxin-1, Spinocerebellar ataxia type 1 protein
Human: P54253, Mouse: P54254
Human: 6310